[A24-109] Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71
Last updated 19.12.2024
Project no.:
A24-109
Commission:
Commission awarded on 12.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy, and who are candidates for high-dose therapy
Unchanged after addendum: hint of minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-109
| Project no. | Title | Status |
|---|---|---|
| A24-71 | Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-12-19 A G-BA decision was published.